Okawaki M - Search Results

1

Dose-finding study of anti-CD25 antibody for targeting regulatory T cells in locoregional immunotherapy of malignant effusion.

Okawaki M, Yamaguchi Y, Okita R, Ohara M, Okada M. Okawaki M, et al. Hiroshima J Med Sci. 2008 Mar;57(1):37-46. Hiroshima J Med Sci. 2008. PMID: 18578365

2

HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.

Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A, Toge T. Yamaguchi Y, et al. Among authors: okawaki m. Anticancer Res. 2005 Mar-Apr;25(2A):827-32. Anticancer Res. 2005. PMID: 15868915 Free article.

3

[Surgical stress].

Yamaguchi Y, Hihara J, Ohara M, Nagamine I, Ikeda T, Okawaki M, Hironaka K, Matsuura K, Okita R, Ohshita A, Shimizu K. Yamaguchi Y, et al. Among authors: okawaki m. Nihon Geka Gakkai Zasshi. 2005 Jul;106(7):444-8. Nihon Geka Gakkai Zasshi. 2005. PMID: 16045189 Review. Japanese. No abstract available.

4

Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.

Yamaguchi Y, Ohta K, Kawabuchi Y, Ohshita A, Okita R, Okawaki M, Hironaka K, Matsuura K, Toge T. Yamaguchi Y, et al. Among authors: okawaki m. Anticancer Res. 2005 May-Jun;25(3c):2407-15. Anticancer Res. 2005. PMID: 16080467 Free article. Clinical Trial.

5

Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.

Yamaguchi Y, Hihara J, Hironaka K, Ohshita A, Okita R, Okawaki M, Matsuura K, Nagamine I, Ikeda T, Ohara M, Hamai Y. Yamaguchi Y, et al. Among authors: okawaki m. Oncol Rep. 2006 Apr;15(4):895-901. Oncol Rep. 2006. PMID: 16525677 Clinical Trial.

6

Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells.

Yamaguchi Y, Ohshita A, Hironaka K, Okita R, Okawaki M, Matsuura K, Nagamine I, Ikeda T, Ohara M, Hihara J. Yamaguchi Y, et al. Among authors: okawaki m. Oncol Rep. 2006 Jul;16(1):165-9. Oncol Rep. 2006. PMID: 16786141

7

Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432.

Hironaka K, Yamaguchi Y, Okita R, Okawaki M, Nagamine I. Hironaka K, et al. Among authors: okawaki m. Anticancer Res. 2006 Sep-Oct;26(5B):3701-7. Anticancer Res. 2006. PMID: 17094388 Free article.

8

Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer.

Okita R, Yamaguchi Y, Ohara M, Hironaka K, Okawaki M, Nagamine I, Ikeda T, Emi A, Hihara J, Okada M. Okita R, et al. Among authors: okawaki m. Int J Oncol. 2009 Feb;34(2):563-72. Int J Oncol. 2009. PMID: 19148493

9

[Current Cancer Immunotherapy Using Activated Lymphocytes - Do Lymphocytes Actually Recognize Cancer Cells ?].

Yamaguchi Y, Katata Y, Okawaki M, Yamamura M, Sawaki A. Yamaguchi Y, et al. Among authors: okawaki m. Gan To Kagaku Ryoho. 2015 Sep;42(9):1031-5. Gan To Kagaku Ryoho. 2015. PMID: 26469157 Review. Japanese.

10

A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic Cancer.

Yamaguchi Y, Katata Y, Okawaki M, Sawaki A, Yamamura M. Yamaguchi Y, et al. Among authors: okawaki m. Anticancer Res. 2016 May;36(5):2307-13. Anticancer Res. 2016. Retraction in: Anticancer Res. 2021 Aug;41(8):4181. doi: 10.21873/anticanres.41.8.4181 PMID: 27127137 Retracted.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters